The issuer is solely responsible for the content of this announcement.

TUESDAY, April 8, 2025 (HealthDay News) -- Federal cuts to funding could “decimate” medical research in the United States, delaying cures and costing countless lives, according to a leader in cancer ...

Discover how an emerging technology called tRNA therapy could become the next big thing in genetic disease treatment.

South Korean researchers have, for the first time in the world, uncovered how messenger ribonucleic acid (mRNA) vaccines ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

While AI offers remarkable efficiency, the pharmaceutical industry must address concerns about “black box” predictions – AI ...

Not just IgG4 antibodies that become predominant in the many-jabbed, but also lesser studied IgG2, researchers find. NIH ...

MRNA, NVAX Price Action: At the time of publication, Moderna shares were down 5.70% at $31.91 and Novavax shares were down 3.37% at $7.30, according to Benzinga Pro.

The vaccine — using messenger RNA (mRNA) technology similar to that found in some Covid vaccines — activated tumour-targeting immune cells that persisted for nearly four years after surgery in ...

U.S. health agency leadership and policymakers seem intent on undermining trust in mRNA, the technology that saved millions of lives during the COVID pandemic and has shown promise in addressing a ...

For years, scientists worldwide have been experimenting with messenger RNA (mRNA) vaccines, unable to secure the funding or interest to reach the answer. This is due to the fact that mRNA degrades ...